Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06141447 · ClinicalTrials.gov registry record · Phase 2

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

A Phase 2 study of Hemorrhage, sponsored by University of Colorado, Denver.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT06141447 is a Phase 2 study of Hemorrhage that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 150 participants, below the 259-participant average among 20 other Hemorrhage trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06141447, a Phase 2 study of Hemorrhage, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D\&E) in the clinic setting.

Conditions Studied

Interventions

  • DRUG Normal saline
  • DRUG Oxytocin + normal saline

Study Locations (1)

Colorado

  • Comprehensive Women's Health Center - Denver

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-05-02
Est. Completion 2026-11-02
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT06141447

The ClinicalTrials.gov registry entry for NCT06141447 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 20 other Hemorrhage trials with a reported enrollment target (42% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.

NCT06141447 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT06141447 about?

NCT06141447 is a clinical study titled "Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation". The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D\&E) in the clinic setting.

What is the current status of trial NCT06141447?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-05-02. Estimated completion is 2026-11-02.

What conditions does trial NCT06141447 study?

This clinical trial studies the following conditions: Hemorrhage.

What interventions are being tested in trial NCT06141447?

The interventions under investigation include: Normal saline (DRUG), Oxytocin + normal saline (DRUG).

Who is sponsoring clinical trial NCT06141447?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06141447 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.